To include your compound in the COVID-19 Resource Center, submit it here.

NEA, Versant back ophthalmic play Oyster Point with $22M A round

On Nov. 7, ophthalmic play Oyster Point Pharmaceuticals Inc. (San Francisco, Calif.) raised $22 million in a series

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE